RecruitingNCT04628429
Autonomic function, migraine attacks, and medicines targeting CGRP
About this title
Read the official source — NCT04628429Observational studyAges 18–64AustriaAnxiety
Understand this study
Who could participate?
Listed age limits: 18 years to 64 years.
- Listed locations
- ViennaSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 1, 2020
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- Medical University of Vienna
- Sponsor type
- University
- Study type
- Observational
- Intervention type
- Drug
- Locations
- Austria
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT04628429
- Official title
Show the full official title
Autonomic Functions in Migraine Patients as a Function of Migraine Status and CGRP Inhibition
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Vienna
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Medical University of Vienna, a university.
Does this study involve medication?
Yes. The study involves medication, including Erenumab, Galcanezumab and Fremanezumab.
Who can participate?
Listed age limits: 18 years to 64 years.
Is this study still recruiting?
The registry lists this study as recruiting.
